SearchDictionaryMobileLogin

Acellular Vaccines

Subscribe to Selected New Research on Acellular Vaccines
91  relevant articles (9 outcomes, 13 trials/studies) found for this Bio-Agent

Description: Vaccines that are produced by using only the antigenic part of the disease causing organism. They often require a "booster" every few years to maintain their effectiveness.

Also Known As:
Vaccines, Acellular

Relationship Network

Bio-Agent Context: Research Results

-
Complex Mixtures: 314
-
Biological Products
-
Vaccines: 15360
-
Subunit Vaccines: 390
-
Acellular Vaccines: 91
*
Diphtheria-Tetanus-acellular Pertussis Vaccines: 147

Experts

1. Tinnion, O N: 2 articles (01/2006 - 01/2000)
2. Hanlon, M: 2 articles (01/2006 - 01/2000)
3. Hanlon, Mark: 1 article (01/2008)
4. Tinnion, Owen: 1 article (01/2008)
5. Keeble, James R: 1 article (01/2004)
6. Dagg, Belinda M: 1 article (01/2004)
7. Xing, Dorothy: 1 article (01/2004)
8. Walker, K Barry: 1 article (01/2004)
9. Whitmore, Katie M: 1 article (01/2004)
10. Carter, Clive R D: 1 article (01/2004)

Related Diseases

1. Whooping Cough (Pertussis)
2. Tetanus
01/01/1997 - "Despite significantly lower tetanus potencies of the acellular vaccines in laboratory tests, no differences were found in tetanus anti-toxin responses in children."
03/01/1992 - "Whereas control of pertussis in the United States may be further improved through increased levels of diphtheria-tetanus-pertussis vaccination among eligible infants and children, the use of acellular vaccines in adolescents and adults may also be needed to reduce the burden of pertussis in very young infants."
12/01/2005 - "Acellular vaccines against diphtheria-tetanus-pertussis (acellular pertussis) (DTaP) are being progressively introduced into vaccination programs worldwide, with the aim of reducing T-helper 1 (Th1)-associated reactogenicity associated with the cellular diphtheria-tetanus-pertussis (whole-cell pertussis) (DTwP) vaccine. "
02/01/2000 - " (5) In the absence of direct comparisons with the cellular pertussis vaccine available in France in tetravalent or pentavalent vaccines, indirect evidence and data from a trial comparing the acellular two-component vaccine with the cellular vaccine (Vaxicoq degrees ) marketed in France (combined with diphtheria and tetanus valencies) suggest that clinical protection is slightly lower after primary vaccination with the two acellular vaccines. "
06/01/1998 - "Recipients of acellular vaccines developed higher anti-FHA concentrations and more rapid anti-PT serological responses that infants who received whole cell pertussis vaccine combined with diphtheria and tetanus toxoids (DPT). "
Order ALL the reference details at left...
3. Diphtheria
03/01/1992 - "Whereas control of pertussis in the United States may be further improved through increased levels of diphtheria-tetanus-pertussis vaccination among eligible infants and children, the use of acellular vaccines in adolescents and adults may also be needed to reduce the burden of pertussis in very young infants."
12/01/2005 - "Acellular vaccines against diphtheria-tetanus-pertussis (acellular pertussis) (DTaP) are being progressively introduced into vaccination programs worldwide, with the aim of reducing T-helper 1 (Th1)-associated reactogenicity associated with the cellular diphtheria-tetanus-pertussis (whole-cell pertussis) (DTwP) vaccine. "
02/01/2000 - " (5) In the absence of direct comparisons with the cellular pertussis vaccine available in France in tetravalent or pentavalent vaccines, indirect evidence and data from a trial comparing the acellular two-component vaccine with the cellular vaccine (Vaxicoq degrees ) marketed in France (combined with diphtheria and tetanus valencies) suggest that clinical protection is slightly lower after primary vaccination with the two acellular vaccines. "
06/01/1998 - "Recipients of acellular vaccines developed higher anti-FHA concentrations and more rapid anti-PT serological responses that infants who received whole cell pertussis vaccine combined with diphtheria and tetanus toxoids (DPT). "
03/01/1996 - "Immunogenicity of the acellular vaccines, persistence of antibodies and adverse reactions were compared with those achieved with a whole-cell diphtheria-pertussis-tetanus (DPT) vaccine. "
Order ALL the reference details at left...
4. Rubella (German Measles)
5. Poliomyelitis (Polio)

Related Drugs and Biologics

1. Vaccines
2. Antibodies
3. Antigens
4. Pertussis Toxin
5. pertactin
6. Hemagglutinins (Hemagglutinin)
7. Diphtheria-Tetanus-Pertussis Vaccine (DPT Vaccine)
8. Pertussis Vaccine
9. Diphtheria-Tetanus-acellular Pertussis Vaccines (Tripedia)
10. Virulence Factors (Pathogenicity Factors)

Related Therapies and Procedures

1. Injections

Best Treatments:
Research Summary Report
on Whooping Cough

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.
  • Free Updates for 1 Year
  • All 288 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 50 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Reference Details
  • Sample PDF Report on Psoriasis >>
Price:$24.00 & Delivery via PDF download
updates for 1 year
Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License Details >>
Price:$490.00 access via web interface
1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.
  • Access from any web enabled PDA or Phone
  • Trial references
  • All the Positive Outcomes
  • Drug and Therapy searches
  • Full Article Reference Details
  • Try Mobile Interface >>
Price:$45.00 access via "curehunter.com/m"
1 year subscription
Proceed to Checkout >>